A carregar...
Overview of Humira(®) biosimilars: current European landscape and future implications
Humira(®) (adalimumab) by AbbVie has been the top-selling biologic drug product for the last few years – reaching nearly $20 billion in annual sales in 2018. Upon the October 2018 release of four adalimumab biosimilars into the European market, those sales began to shrink. By the end of 2019, the an...
Na minha lista:
| Publicado no: | J Pharm Sci |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8014989/ https://ncbi.nlm.nih.gov/pubmed/33556387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xphs.2021.02.003 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|